Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
8 studies found for:    cerebral palsy | United States, Washington
Show Display Options
Rank Status Study
1 Completed
Has Results
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
Condition: Cerebral Palsy (CP)
Interventions: Drug: dalfampridine-ER 10mg;   Other: Placebo
2 Withdrawn Botulinum Toxin (BOTOX) for Cerebral Palsy
Conditions: Cerebral Palsy;   Muscle Spasticity
Intervention: Drug: Botulinum toxin type A
3 Completed Orthotics in Ambulatory Cerebral Palsy
Condition: Cerebral Palsy
Interventions: Device: SAFO worn;   Other: SAFO  not worn
4 Completed Activity and Participation in Ambulatory Cerebral Palsy
Condition: Cerebral Palsy
5 Completed Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity
Conditions: Spasticity;   Cerebral Palsy
Intervention: Drug: baclofen
6 Unknown  Relaxation Training to Decrease Pain and Improve Function in Adolescents With Cerebral Palsy
Condition: Cerebral Palsy
Intervention: Behavioral: biofeedback-monitored relaxation training
7 Recruiting Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)
Condition: Extreme Prematurity
Intervention: Drug: Epo
8 Completed
Has Results
Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP);   Drug: 15 mg fampridine-SR (4-aminopyridine, 4-AP);   Drug: 20 mg fampridine-SR (4-aminopyridine, 4-AP)

Indicates status has not been verified in more than two years